Effects of urokinase on renal interstitial fibrosis and transforming growth factor-beta1 in the kidney of rats with chronic cyclosporine A nephropathy.
- Author:
Yin WANG
1
;
Jun-rong TONG
;
Zheng-mao LUO
;
Feng HE
;
Li MA
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cyclosporine; Fibrosis; prevention & control; Kidney; pathology; Kidney Diseases; chemically induced; drug therapy; pathology; Male; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; metabolism; Urokinase-Type Plasminogen Activator; pharmacology; therapeutic use
- From: Journal of Southern Medical University 2009;29(12):2449-2452
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of urokinase on renal interstitial fibrosis and transforming growth factor-beta1 (TGF-beta1) in the kidney of rats with chronic cyclosporine A nephropathy.
METHODSMale Sprague-Dawley rats on low-salt diet were randomly divided into control (VH), CsA-treated (CsA), CsA+2000 U/kg.day uPA (CsA+U2) and CsA+6000 U.kg.3 days (CsA+U6) groups. The rats were given CsA intragastrically for 4 weeks to prepare CsA-induced chronic nephropathy model. Masson staining was used to examine fibrin deposition. Western blotting and reversal transcription polymerase chain reaction were employed to evaluate urokinase-type plasminogen activator (uPA) and TGF-beta1 protein and gene expressions, respectively.
RESULTSCsA can increase fibrin deposition and the expression of TGF-beta1 in the renal tissue, which were significantly reduced after uPA treatment (P<0.05).
CONCLUSIONContinuous low-dose uPA treatment can reduce renal interstitial fibrosis in rats possibly in association with its inhibitory effect on TGF-beta1 expression.
